share_log

Ladenburg Thalmann Maintains Buy on UroGen Pharma, Raises Price Target to $53.5

Ladenburg Thalmann Maintains Buy on UroGen Pharma, Raises Price Target to $53.5

Ladenburg Thalmann維持對UroGen藥業的買入評級,將價格目標上調至53.5美元。
Benzinga ·  06/14 14:42

Ladenburg Thalmann analyst Matthew Kaplan maintains UroGen Pharma (NASDAQ:URGN) with a Buy and raises the price target from $48 to $53.5.

Ladenburg Thalmann分析師Matthew Kaplan維持對UroGen Pharma(納斯達克股票代碼:URGN)的買入評級,將目標價從48美元上調至53.5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論